PURPOSE: The aim of the study was to examine the impact of the severity of asthma exacerbations on the patients’ satisfaction with inhaled medication.
METHODS: In the cross-sectional study, the “Satisfaction with Inhaled Asthma Treatment Questionnaire” (SATQ) was administered in 119 ambulatory asthma patients (44 male, mean FEV1 was 74.8 ± 23.2% predicted, mean age was 44.5 ± 16.9 years, average duration of asthma was 11.9 ± 9.2 years). SATQ has four domains that reflect different aspects of satisfaction: effectiveness of treatment, ease of use, medication burden, and side-effects and worries. The scores are calculated for the overall satisfaction as well as for the individual domains (on the 7-point scale). The bigger the score the better the satisfaction.The patients were assigned into three severity groups depending of their FEV1 readings: Group I (54 pts) –FEV1 80% predicted and above; Group II (34 pts) –FEV1 between 60% and 79% predicted; Group III (31 pts) –FEV1 < 60% predicted.
RESULTS: Mean overall SATQ scores were 5.83 in group I, 5.69 in group II and 5.02 in group III. Statistically highly significant difference between all SATQ scores (except for medication burden domain) with regard to the patient groups was established by means of ANOVA (for overall SATQ score F = 11.86, p < 0.001). Pearson’s coefficient of linear correlation also showed a statistically highly significant correlation between the overall SATQ scores and the FEV1 values (r = 0.342, p < 0.001).
CONCLUSION: Patients’ satisfaction with inhaled medication, that could be well determined by the SATQ questionnaire, strongly reflects the severity of asthma exacerbations as assessed by means of the spirometry.
CLINICAL IMPLICATIONS: Satisfaction with inhaled asthma treatment could be successfully used as an outcome in asthma clinical research and practice.
DISCLOSURE: Branislav Gvozdenovic, None.